HIV/AIDS Topics CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 14 February 2017 00:00
- Written by Liz Highleyman
Bictegravir, an investigational integrase inhibitor from Gilead Sciences, was highly potent, well tolerated and worked as well as dolutegravir (Tivcay) in a Phase 2 clinical trial, according to study results presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle and published online in The Lancet HIV.
CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 February 2017 00:00
- Written by Liz Highleyman
People who switched from standard antiretroviral therapy to a 2-drug regimen of dolutegravir (Tivicay) plus rilpivirine (Edurant) were able to maintain an undetectable viral load for 48 weeks in a pair of late-stage clinical trials, according to a late-breaking report at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.
Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies
- Details
- Category: HIV Treatment
- Published on Tuesday, 27 December 2016 00:00
- Written by Liz Highleyman
Switching to a 2-drug regimen of dolutegravir plus rilpivirine maintained viral suppression among people on successful 3- or 4-drug antiretroviral therapy (ART) in a pair of Phase 3 clinical trials, according to an announcement last week from ViiV Healthcare.
HIVandHepatitis.com 2016 Conference Coverage
- Details
- Category: HIV Treatment
- Published on Thursday, 29 December 2016 00:00
- Written by HIVandHepatitis.com
Article listings by topic for HIVandHepatitis.com conference coverage in 2016, including the Conference on Retroviruses and Opportunistic Infections, EASL International Liver Congress, International AIDS Conference, and AASLD Liver Meeting.
2. Quicker, Simpler, and Better Antiretroviral Therapy
- Details
- Category: HIV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Modern antiretroviral therapy (ART) is highly effective and well-tolerated, but researchers continue to refine, streamline, and optimize treatment strategies. Studies presented this year show the benefits of starting ART as soon as possible after HIV diagnosis and suggest that fewer drugs taken less often may be effective for many people.
Top 10 HIV and Hepatitis Stories of 2016
- Details
- Category: HIV Treatment
- Published on Wednesday, 28 December 2016 00:00
- Written by HIVandHepatitis.com
Simplification and optimization of antiretroviral therapy for HIV, wider use of pre-exposure prophylaxis (PrEP), a growing appreciation that people with undetectable viral load do not transmit HIV, and an expanded armamentarium of treatments for hepatitis C were among the top HIV and viral hepatitis headlines this year. Here's a look back at some of our biggest news from 2016.
3. Renewed Focus on HIV Vaccines and Antibodies
- Details
- Category: Search for a Cure
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
Researchers intensified the search for novel types of therapies to prevent, treat, and potentially cure HIV, including immune-based strategies such as antibodies and vaccines.
More Articles...
- UCSF/amfAR HIV Cure Summit Reviews Progress in Cure-Related Research
- Advocates Call for More Research on Immune-Enhancing Therapies for People with HIV
- World AIDS Day: 18 Million Now on HIV Treatment but Many Still Lack Access
- HIV Glasgow: 4-Days-On-3-Days-Off HIV Treatment Controls Viral Load in Pilot Study
- HIV Glasgow: Long-Acting HIV Fusion Inhibitor Albuvirtide Regimen Matches Standard Therapy
Web Design and Development by